Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd > Pp must be filled.

<< Previous

Bullboard Posts

Next >>

Comment by threefiftynineon Jul 08, 2020 5:25pm

59 Views

Post# 31241972

RE:RE:Pp must be filled.

No!!---58 .8 x .085 =just over $5 million---the 2$million wont enter this picture and if it does it will be a lot less than 58 million shares---more like under 25 million shares---do the math --less dilution mind you---approx. figures

<< Previous

Bullboard Posts

Next >>

Hyundai partners with BlackBerry for next-gen digital cockpit platform